Clinical and Molecular Hepatology (대한간학회지)

The Korean Association for the Study of the Liver (대한간학회)
권호 표지
DOI QR코드

DOI QR Code

The role of gut-liver axis in the pathogenesis of liver cirrhosis and portal hypertension

  • Seo, Yeon Seok (Gastroenterology Research Unit, Mayo Clinic) ;
  • Shah, Vijay H. (Gastroenterology Research Unit, Mayo Clinic)
  • Published : 2012.12.25
⟨ Previous Next ⟩

Abstract

Because of the anatomical position and its unique vascular system, the liver is susceptible to the exposure to the microbial products from the gut. Although large amount of microbes colonize in the gut, translocation of the microbes or microbial products into the liver and systemic circulation is prevented by gut epithelial barrier function and cleansing and detoxifying functions of the liver in healthy subjects. However, when the intestinal barrier function is disrupted, large amount of bacterial products can enter into the liver and systemic circulation and induce inflammation through their receptors. Nowadays, there have been various reports suggesting the role of gut flora and bacterial translocation in the pathogenesis of chronic liver disease and portal hypertension. This review summarizes the current knowledge about bacterial translocation and its contribution to the pathogenesis of chronic liver diseases and portal hypertension.

Keywords

References

  1. Shah VJ, Kamath PS. Portal hypertension and gastrointestinal bleeding. In: Feldman M, Fridman LS, Brandt LJ, eds. Sleisenger and Fordtran's gastrointestinal and liver disease, 9th ed. Philadelphia PA: Saunders Elsevier, 2010:1489-1516.
  2. Rao R. Endotoxemia and gut barrier dysfunction in alcoholic liver disease. Hepatology 2009;50:638-644.
  3. Seki E, Brenner DA. Toll-like receptors and adaptor molecules in liver disease: update. Hepatology 2008;48:322-335.
  4. Rao RK, Seth A, Sheth P. Recent Advances in Alcoholic Liver Disease I. Role of intestinal permeability and endotoxemia in alcoholic liver disease. Am J Physiol Gastrointest Liver Physiol 2004;286:G881-G884.
  5. Rao RK. Acetaldehyde-induced increase in paracellular permeability in Caco-2 cell monolayer. Alcohol Clin Exp Res 1998;22:1724-1730.
  6. Keshavarzian A, Farhadi A, Forsyth CB, Rangan J, Jakate S, Shaikh M, et al. Evidence that chronic alcohol exposure promotes intestinal oxidative stress, intestinal hyperpermeability and endotoxemia prior to development of alcoholic steatohepatitis in rats. J Hepatol 2009;50:538-547.
  7. Keshavarzian A, Holmes EW, Patel M, Iber F, Fields JZ, Pethkar S. Leaky gut in alcoholic cirrhosis: a possible mechanism for alcoholinduced liver damage. Am J Gastroenterol 1999;94:200-207.
  8. Yumuk Z, Ozdemirci S, Erden BF, Dundar V. The effect of long-term ethanol feeding on Brucella melitensis infection of rats. Alcohol Alcohol 2001;36:314-317.
  9. Kavanaugh MJ, Clark C, Goto M, Kovacs EJ, Gamelli RL, Sayeed MM, et al. Effect of acute alcohol ingestion prior to burn injury on intestinal bacterial growth and barrier function. Burns 2005;31:290-296.
  10. Wheeler MD, Kono H, Yin M, Nakagami M, Uesugi T, Arteel GE, et al. The role of Kupffer cell oxidant production in early ethanolinduced liver disease. Free Radic Biol Med 2001;31:1544-1549.
  11. Thakur V, McMullen MR, Pritchard MT, Nagy LE. Regulation of macrophage activation in alcoholic liver disease. J Gastroenterol Hepatol 2007;22(Suppl 1):S53- S56.
  12. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 2009;49:1877-1887.
  13. Huang Y, Blatt LM, Taylor MW. Type 1 interferon as an antiinflammatory agent: inhibition of lipopolysaccharide-induced interleukin-1 beta and induction of interleukin-1 receptor antagonist. J Interferon Cytokine Res 1995;15:317-321.
  14. Csak T, Velayudham A, Hritz I, Petrasek J, Levin I, Lippai D, et al. Deficiency in myeloid differentiation factor-2 and toll-like receptor 4 expression attenuates nonalcoholic steatohepatitis and fibrosis in mice. Am J Physiol Gastrointest Liver Physiol 2011;300:G433-G441.
  15. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, et al. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: role of endotoxin. J Hepatol 2008;48:983-992.
  16. Farhadi A, Gundlapalli S, Shaikh M, Frantzides C, Harrell L, Kwasny MM, et al. Susceptibility to gut leakiness: a possible mechanism for endotoxaemia in non-alcoholic steatohepatitis. Liver Int 2008;28:1026-1033.
  17. Bigatello LM, Broitman SA, Fattori L, Di Paoli M, Pontello M, Bevilacqua G, et al. Endotoxemia, encephalopathy, and mortality in cirrhotic patients. Am J Gastroenterol 1987;82:11-15.
  18. Lin RS, Lee FY, Lee SD, Tsai YT, Lin HC, Lu RH, et al. Endotoxemia in patients with chronic liver diseases: relationship to severity of liver diseases, presence of esophageal varices, and hyperdynamic circulation. J Hepatol 1995;22:165-172.
  19. Michie HR, Manogue KR, Spriggs DR, Revhaug A, O'Dwyer S, Dinarello CA, et al. Detection of circulating tumor necrosis factor after endotoxin administration. N Engl J Med 1988;318:1481-1486.
  20. van Deventer SJ, Buller HR, ten Cate JW, Aarden LA, Hack CE, Sturk A. Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolytic, and complement pathways. Blood 1990;76:2520-2526.
  21. Mathison JC, Ulevitch RJ. The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits. J Immunol 1979;123:2133-2143.
  22. Zlydaszyk JC, Moon RJ. Fate of 51Cr-labeled lipopolysaccharide in tissue culture cells and livers of normal mice. Infect Immun 1976;14:100-105.
  23. Lumsden AB, Henderson JM, Kutner MH. Endotoxin levels measured by a chromogenic assay in portal, hepatic and peripheral venous blood in patients with cirrhosis. Hepatology 1988;8:232-236.
  24. Szabo G, Bala S, Petrasek J, Gattu A. Gut-liver axis and sensing microbes. Dig Dis 2010;28:737-744.
  25. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411-420.
  26. Varol C, Zigmond E, Jung S. Securing the immune tightrope: mononuclear phagocytes in the intestinal lamina propria. Nat Rev Immunol 2010;10:415-426.
  27. Varol C, Vallon-Eberhard A, Elinav E, Aychek T, Shapira Y, Luche H, et al. Intestinal lamina propria dendritic cell subsets have different origin and functions. Immunity 2009;31:502-512.
  28. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009;27:147-163.
  29. Nakao A, Taki S, Yasui M, Kimura Y, Nonami T, Harada A, et al. The fate of intravenously injected endotoxin in normal rats and in rats with liver failure. Hepatology 1994;19:1251-1256.
  30. Catala M, Anton A, Portoles MT. Characterization of the simultaneous binding of Escherichia coli endotoxin to Kupffer and endothelial liver cells by flow cytometry. Cytometry 1999;36:123-130.
  31. Dolganiuc A, Norkina O, Kodys K, Catalano D, Bakis G, Marshall C, et al. Viral and host factors induce macrophage activation and loss of toll-like receptor tolerance in chronic HCV infection. Gastroenterology 2007;133:1627-1636.
  32. Roth J, McClellan JL, Kluger MJ, Zeisberger E. Attenuation of fever and release of cytokines after repeated injections of lipopolysaccharide in guinea-pigs. J Physiol 1994;477:177-185.
  33. Szabo G, Mandrekar P, Girouard L, Catalano D. Regulation of human monocyte functions by acute ethanol treatment: decreased tumor necrosis factor-alpha, interleukin-1 beta and elevated interleukin- 10, and transforming growth factor-beta production. Alcohol Clin Exp Res 1996;20:900-907.
  34. McClain CJ, Cohen DA. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989;9:349-351.
  35. Vreugdenhil AC, Snoek AM, van 't Veer C, Greve JW, Buurman WA. LPS-binding protein circulates in association with apoB-containing lipoproteins and enhances endotoxin-LDL/VLDL interaction. J Clin Invest 2001;107:225-234.
  36. Medvedev AE, Lentschat A, Wahl LM, Golenbock DT, Vogel SN. Dysregulation of LPS-induced Toll-like receptor 4-MyD88 complex formation and IL-1 receptor-associated kinase 1 activation in endotoxin- tolerant cells. J Immunol 2002;169:5209-5216.
  37. Garcia-Tsao G, Wiest R. Gut microflora in the pathogenesis of the complications of cirrhosis. Best Pract Res Clin Gastroenterol 2004;18:353-372.
  38. Riordan SM, Williams R. Gut flora and hepatic encephalopathy in patients with cirrhosis. N Engl J Med 2010;362:1140-1142.
  39. Berg RD, Garlington AW. Translocation of certain indigenous bacteria from the gastrointestinal tract to the mesenteric lymph nodes and other organs in a gnotobiotic mouse model. Infect Immun 1979;23:403-411.
  40. Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005;41:422-433.
  41. Pradere JP, Troeger JS, Dapito DH, Mencin AA, Schwabe RF. Toll-like receptor 4 and hepatic fibrogenesis. Semin Liver Dis 2010;30:232-244.
  42. Son G, Kremer M, Hines IN. Contribution of gut bacteria to liver pathobiology. Gastroenterol Res Pract. 2010;2010. pii: 453563.
  43. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol 2008;8:411-420.
  44. Backhed F, Ley RE, Sonnenburg JL, Peterson DA, Gordon JI. Hostbacterial mutualism in the human intestine. Science 2005;307:1915- 1920.
  45. Rao RK. Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. Methods Mol Biol 2008;447:171-183.
  46. Tang Y, Forsyth CB, Farhadi A, Rangan J, Jakate S, Shaikh M, et al. Nitric oxide-mediated intestinal injury is required for alcoholinduced gut leakiness and liver damage. Alcohol Clin Exp Res 2009;33:1220-1230.
  47. Yajima S, Morisaki H, Serita R, Suzuki T, Katori N, Asahara T, et al. Tumor necrosis factor-alpha mediates hyperglycemiaaugmented gut barrier dysfunction in endotoxemia. Crit Care Med 2009;37:1024-1030.
  48. Miettinen TA. Lipid absorption, bile acids, and cholesterol metabolism in patients with chronic liver disease. Gut 1972;13:682-689.
  49. Sung JY, Shaffer EA, Costerton JW. Antibacterial activity of bile salts against common biliary pathogens. Effects of hydrophobicity of the molecule and in the presence of phospholipids. Dig Dis Sci 1993;38:2104-2112.
  50. Gunnarsdottir SA, Sadik R, Shev S, Simren M, Sjövall H, Stotzer PO, et al. Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension. Am J Gastroenterol 2003;98:1362-1370.
  51. Van Thiel DH, Fagiuoli S, Wright HI, Chien MC, Gavaler JS. Gastrointestinal transit in cirrhotic patients: effect of hepatic encephalopathy and its treatment. Hepatology 1994;19:67-71.
  52. Madrid AM, Cumsille F, Defilippi C. Altered small bowel motility in patients with liver cirrhosis depends on severity of liver disease. Dig Dis Sci 1997;42:738-742.
  53. Madrid AM, Brahm J, Buckel E, Silva G, Defilippi C. Orthotopic liver transplantation improves small bowel motility disorders in cirrhotic patients. Am J Gastroenterol 1997;92:1044-1045.
  54. Robinson CJ, Bohannan BJ, Young VB. From structure to function: the ecology of host-associated microbial communities. Microbiol Mol Biol Rev 2010;74:453-476.
  55. Gillevet P, Sikaroodi M, Keshavarzian A, Mutlu EA. Quantitative assessment of the human gut microbiome using multitag pyrosequencing. Chem Biodivers 2010;7:1065-1075.
  56. Zeuzem S. Gut-liver axis. Int J Colorectal Dis 2000;15:59-82.
  57. Norman K, Pirlich M. Gastrointestinal tract in liver disease: which organ is sick? Curr Opin Clin Nutr Metab Care 2008;11:613-619.
  58. Chen Y, Yang F, Lu H, Wang B, Chen Y, Lei D, et al. Characterization of fecal microbial communities in patients with liver cirrhosis. Hepatology 2011;54:562-572.
  59. Lu H, Wu Z, Xu W, Yang J, Chen Y, Li L. Intestinal microbiota was assessed in cirrhotic patients with hepatitis B virus infection. Intestinal microbiota of HBV cirrhotic patients. Microb Ecol 2011;61:693-703.
  60. Gomez-Hurtado I, Santacruz A, Peiro G, Zapater P, Gutierrez A, Perez-Mateo M, et al. Gut microbiota dysbiosis is associated with inflammation and bacterial translocation in mice with CCl4-induced fibrosis. PLoS One 2011;6:e23037.
  61. Zhang W, Gu Y, Chen Y, Deng H, Chen L, Chen S, et al. Intestinal flora imbalance results in altered bacterial translocation and liver function in rats with experimental cirrhosis. Eur J Gastroenterol Hepatol 2010;22:1481-1486.
  62. Grange JD, Roulot D, Pelletier G, Pariente EA, Denis J, Ink O, et al. Norfloxacin primary prophylaxis of bacterial infections in cirrhotic patients with ascites: a double-blind randomized trial. J Hepatol 1998;29:430-436.
  63. Liu Q, Duan ZP, Ha DK, Bengmark S, Kurtovic J, Riordan SM. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004;39:1441-1449.
  64. Novella M, Sola R, Soriano G, Andreu M, Gana J, Ortiz J, et al. Continuous versus inpatient prophylaxis of the first episode of spontaneous bacterial peritonitis with norfloxacin. Hepatology 1997;25:532-536.
  65. Rasaratnam B, Kaye D, Jennings G, Dudley F, Chin-Dusting J. The effect of selective intestinal decontamination on the hyperdynamic circulatory state in cirrhosis. A randomized trial. Ann Intern Med 2003;139:186-193.
  66. Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012;482:179-185.
  67. Mandrekar P, Bala S, Catalano D, Kodys K, Szabo G. The opposite effects of acute and chronic alcohol on lipopolysaccharide-induced inflammation are linked to IRAK-M in human monocytes. J Immunol 2009;183:1320-1327.
  68. Nagy LE. Recent insights into the role of the innate immune system in the development of alcoholic liver disease. Exp Biol Med (Maywood) 2003;228:882-890.
  69. Wu D, Cederbaum AI. Oxidative stress and alcoholic liver disease. Semin Liver Dis 2009;29:141-154.
  70. Szabo G, Mandrekar P, Petrasek J, Catalano D. The unfolding web of innate immune dysregulation in alcoholic liver injury. Alcohol Clin Exp Res 2011;35:782-786.
  71. Adachi Y, Bradford BU, Gao W, Bojes HK, Thurman RG. Inactivation of Kupffer cells prevents early alcohol-induced liver injury. Hepatology 1994;20:453-460.
  72. Adachi Y, Moore LE, Bradford BU, Gao W, Thurman RG. Antibiotics prevent liver injury in rats following long-term exposure to ethanol. Gastroenterology 1995;108:218-224.
  73. van Rooijen N, Sanders A, van den Berg TK. Apoptosis of macrophages induced by liposome-mediated intracellular delivery of clodronate and propamidine. J Immunol Methods 1996;193:93-99.
  74. Paik YH, Schwabe RF, Bataller R, Russo MP, Jobin C, Brenner DA. Toll-like receptor 4 mediates inflammatory signaling by bacterial lipopolysaccharide in human hepatic stellate cells. Hepatology 2003;37:1043-1055.
  75. Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. S-adenosyl-L-methionine attenuates oxidative stress and hepatic stellate cell activation in an ethanol-LPS-induced fibrotic rat model. Shock 2008;30:197-205.
  76. Quiroz SC, Bucio L, Souza V, Hernandez E, Gonzalez E, Gomez- Quiroz L, et al. Effect of endotoxin pretreatment on hepatic stellate cell response to ethanol and acetaldehyde. J Gastroenterol Hepatol 2001;16:1267-1273.
  77. Rock FL, Hardiman G, Timans JC, Kastelein RA, Bazan JF. A family of human receptors structurally related to Drosophila Toll. Proc Natl Acad Sci U S A 1998;95:588-593.
  78. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997;388:394-397.
  79. Guo J, Friedman SL. Toll-like receptor 4 signaling in liver injury and hepatic fibrogenesis. Fibrogenesis Tissue Repair 2010;3:21.
  80. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006;44:287-298.
  81. Takeuchi O, Akira S. Pattern recognition receptors and inflammation. Cell 2010;140:805-820.
  82. Yamamoto M, Takeda K. Current views of toll-like receptor signaling pathways. Gastroenterol Res Pract 2010;2010:240365.
  83. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science 1998;282:2085-2088.
  84. Shimazu R, Akashi S, Ogata H, Nagai Y, Fukudome K, Miyake K, et al. MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J Exp Med 1999;189:1777-1782.
  85. Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC. CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431-1433.
  86. Mandrekar P, Szabo G. Signalling pathways in alcohol-induced liver inflammation. J Hepatol 2009;50:1258-1266.
  87. Verstak B, Nagpal K, Bottomley SP, Golenbock DT, Hertzog PJ, Mansell A. MyD88 adapter-like (Mal)/TIRAP interaction with TRAF6 is critical for TLR2- and TLR4-mediated NF-kappaB proinflammatory responses. J Biol Chem 2009;284:24192-24203.
  88. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006;124:783-801.
  89. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012;590:447-458.
  90. Schafer SL, Lin R, Moore PA, Hiscott J, Pitha PM. Regulation of type I interferon gene expression by interferon regulatory factor-3. J Biol Chem 1998;273:2714-2720.
  91. Hritz I, Mandrekar P, Velayudham A, Catalano D, Dolganiuc A, Kodys K, et al. The critical role of toll-like receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88. Hepatology 2008;48:1224-1231.
  92. Rivera CA, Adegboyega P, van Rooijen N, Tagalicud A, Allman M, Wallace M. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007;47:571-579.
  93. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010;10:826-837.
  94. Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-426.
  95. Ye Z, Ting JP. NLR, the nucleotide-binding domain leucine-rich repeat containing gene family. Curr Opin Immunol 2008;20:3-9.
  96. Bauernfeind F, Ablasser A, Bartok E, Kim S, Schmid-Burgk J, Cavlar T, et al. Inflammasomes: current understanding and open questions. Cell Mol Life Sci 2011;68:765-783.
  97. Sutterwala FS, Ogura Y, Flavell RA. The inflammasome in pathogen recognition and inflammation. J Leukoc Biol 2007;82:259-264.
  98. Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009;27:229-265.
  99. Agostini L, Martinon F, Burns K, McDermott MF, Hawkins PN, Tschopp J. NALP3 forms an IL-1beta-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-325.
  100. Dinarello CA. Immunological and inflammatory functions of the interleukin-1 family. Annu Rev Immunol 2009;27:519-550.
  101. Bauernfeind F, Bartok E, Rieger A, Franchi L, Nunez G, Hornung V. Cutting edge: reactive oxygen species inhibitors block priming, but not activation, of the NLRP3 inflammasome. J Immunol 2011;187:613-617.
  102. Ganz M, Csak T, Nath B, Szabo G. Lipopolysaccharide induces and activates the Nalp3 inflammasome in the liver. World J Gastroenterol 2011;17:4772-4778.
  103. McClain CJ, Cohen DA, Dinarello CA, Cannon JG, Shedlofsky SI, Kaplan AM. Serum interleukin-1 (IL-1) activity in alcoholic hepatitis. Life Sci 1986;39:1479-1485.
  104. Valles SL, Blanco AM, Azorin I, Guasch R, Pascual M, Gomez-Lechon MJ, et al. Chronic ethanol consumption enhances interleukin-1-mediated signal transduction in rat liver and in cultured hepatocytes. Alcohol Clin Exp Res 2003;27:1979-1986.
  105. Bjarnason I, Peters TJ, Wise RJ. The leaky gut of alcoholism: possible route of entry for toxic compounds. Lancet 1984;1:179-182.
  106. Draper LR, Gyure LA, Hall JG, Robertson D. Effect of alcohol on the integrity of the intestinal epithelium. Gut 1983;24:399-404.
  107. Parlesak A, Schafer C, Schütz T, Bode JC, Bode C. Increased intestinal permeability to macromolecules and endotoxemia in patients with chronic alcohol abuse in different stages of alcohol-induced liver disease. J Hepatol 2000;32:742-747.
  108. Chesta J, Defilippi C. Abnormalities in proximal small bowel motility in patients with cirrhosis. Hepatology 1993;17:828-832.
  109. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997;26:1372-1378.
  110. Ramachandran A, Prabhu R, Thomas S, Reddy JB, Pulimood A, Balasubramanian KA. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002;35:622-629.
  111. Rajkovic IA, Williams R. Abnormalities of neutrophil phagocytosis, intracellular killing and metabolic activity in alcoholic cirrhosis and hepatitis. Hepatology 1986;6:252-262.
  112. Garcia-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995;108:1835-1841.
  113. Gaeta GB, Perna P, Adinolfi LE, Utili R, Ruggiero G. Endotoxemia in a series of 104 patients with chronic liver diseases: prevalence and significance. Digestion 1982;23:239-244.
  114. Bode C, Kugler V, Bode JC. Endotoxemia in patients with alcoholic and non-alcoholic cirrhosis and in subjects with no evidence of chronic liver disease following acute alcohol excess. J Hepatol 1987;4:8-14.
  115. Urbaschek R, McCuskey RS, Rudi V, Becker KP, Stickel F, Urbaschek B, et al. Endotoxin, endotoxin-neutralizing-capacity, sCD14, sICAM-1, and cytokines in patients with various degrees of alcoholic liver disease. Alcohol Clin Exp Res 2001;25:261-268.
  116. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, et al. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (Lond) 2010;7:15.
  117. Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces endotoxemia and severity of experimental alcoholic liver (disease). Proc Soc Exp Biol Med 1994;205:243-247.
  118. Schwabe RF, Seki E, Brenner DA. Toll-like receptor signaling in the liver. Gastroenterology. 2006 May;130(6):1886-900.
  119. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997;94:2557-2562.
  120. Szabo G, Velayudham A, Romics L Jr, Mandrekar P. Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4. Alcohol Clin Exp Res 2005;29(11 Suppl):140S-145S.
  121. Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol 2003;38:681-687.
  122. Li Z, Yang S, Lin H, Huang J, Watkins PA, Moser AB, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003;37:343-350.
  123. Sandler NG, Koh C, Roque A, Eccleston JL, Siegel RB, Demino M, et al. Host response to translocated microbial products predicts outcomes of patients with HBV or HCV infection. Gastroenterology 2011;141:1220-1230, 1230.e1-3.
  124. Steib CJ, Hartmann AC, v Hesler C, Benesic A, Hennenberg M, Bilzer M, et al. Intraperitoneal LPS amplifies portal hypertension in rat liver fibrosis. Lab Invest 2010;90:1024-1032.
  125. Chiva M, Guarner C, Peralta C, Llovet T, Gomez G, Soriano G, et al. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol 2003;15:145-150.
  126. Clements WD, Erwin P, McCaigue MD, Halliday I, Barclay GR, Rowlands BJ. Conclusive evidence of endotoxaemia in biliary obstruction. Gut 1998;42:293-299.
  127. Wiest R, Das S, Cadelina G, Garcia-Tsao G, Milstien S, Groszmann RJ. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999;104:1223-1233.
  128. Tazi KA, Moreau R, Herve P, Dauvergne A, Cazals-Hatem D, Bert F, et al. Norfloxacin reduces aortic NO synthases and proinflammatory cytokine up-regulation in cirrhotic rats: role of Akt signaling. Gastroenterology 2005;129:303-314.
  129. Seki E, De Minicis S, Osterreicher CH, Kluwe J, Osawa Y, Brenner DA, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007;13:1324-1332.
  130. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007;46:297-306.

Cited by

  1. The gut microbiota and the liver: implications for clinical practice vol.7, pp.8, 2013, https://doi.org/10.1586/17474124.2013.848167
  2. Role of a Bacillus subtilis Direct-Fed Microbial on Digesta Viscosity, Bacterial Translocation, and Bone Mineralization in Turkey Poults Fed with a Rye-Based Diet vol.1, pp.None, 2012, https://doi.org/10.3389/fvets.2014.00026
  3. Alcoholic liver disease: Treatment vol.20, pp.36, 2014, https://doi.org/10.3748/wjg.v20.i36.12934
  4. Toll-Like Receptor 2 Activation by β2→1-Fructans Protects Barrier Function of T84 Human Intestinal Epithelial Cells in a Chain Length–Dependent Manner vol.144, pp.7, 2012, https://doi.org/10.3945/jn.114.191643
  5. Evolving Concepts in the Pathogenesis of NASH: Beyond Steatosis and Inflammation vol.15, pp.5, 2012, https://doi.org/10.3390/ijms15058591
  6. n‐3 polyunsaturated fatty acids worsen inflammation and fibrosis in experimental nonalcoholic steatohepatitis vol.34, pp.6, 2012, https://doi.org/10.1111/liv.12500
  7. Effects of Korean Red Ginseng ( Panax ginseng ), urushiol ( Rhus vernicifera Stokes), and probiotics ( Lactobacillus rhamnosus R0011 and Lactobacillus acidophilus R0052) on the gut–liver ax vol.38, pp.3, 2014, https://doi.org/10.1016/j.jgr.2014.04.002
  8. An alteration of the gut-liver axis drives pulmonary inflammation after intoxication and burn injury in mice vol.307, pp.7, 2014, https://doi.org/10.1152/ajpgi.00185.2014
  9. The Role of Intestinal Bacteria Overgrowth in Obesity-Related Nonalcoholic Fatty Liver Disease vol.6, pp.12, 2012, https://doi.org/10.3390/nu6125583
  10. Effect of TU-100, a traditional Japanese medicine, administered after hepatic resection in patients with liver cancer: a multi-center, phase III trial (JFMC40-1001) vol.20, pp.1, 2012, https://doi.org/10.1007/s10147-014-0678-2
  11. Hepatic Hemangioma in Celiac Patients: Data from a Large Consecutive Series vol.2015, pp.None, 2012, https://doi.org/10.1155/2015/749235
  12. Effects of Lycium barbarum on bacterial translocation in thioacetamide-induced liver injury in rats vol.13, pp.3, 2012, https://doi.org/10.1177/1721727x15618413
  13. IGF-1 decreases portal vein endotoxin via regulating intestinal tight junctions and plays a role in attenuating portal hypertension of cirrhotic rats vol.15, pp.None, 2012, https://doi.org/10.1186/s12876-015-0311-5
  14. Role of systemic inflammation in cirrhosis: From pathogenesis to prognosis vol.7, pp.16, 2015, https://doi.org/10.4254/wjh.v7.i16.1974
  15. Gut microbiota and liver diseases vol.21, pp.6, 2012, https://doi.org/10.3748/wjg.v21.i6.1691
  16. Gut-liver axis in liver cirrhosis: How to manage leaky gut and endotoxemia vol.7, pp.3, 2012, https://doi.org/10.4254/wjh.v7.i3.425
  17. The relevance of intestinal dysbiosis in liver transplant candidates vol.17, pp.2, 2012, https://doi.org/10.1111/tid.12352
  18. Effects of probiotics (cultured Lactobacillus subtilis/Streptococcus faecium) in the treatment of alcoholic hepatitis: randomized-controlled multicenter study vol.27, pp.11, 2015, https://doi.org/10.1097/meg.0000000000000458
  19. Gut Microbiota and Host Reaction in Liver Diseases vol.3, pp.4, 2012, https://doi.org/10.3390/microorganisms3040759
  20. Pathogenesis of nonalcoholic steatohepatitis vol.73, pp.10, 2012, https://doi.org/10.1007/s00018-016-2161-x
  21. New treatment options for alcoholic hepatitis vol.22, pp.15, 2012, https://doi.org/10.3748/wjg.v22.i15.3892
  22. Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats vol.310, pp.11, 2012, https://doi.org/10.1152/ajpgi.00428.2015
  23. Dietary capsaicin and antibiotics act synergistically to reduce non-alcoholic fatty liver disease induced by high fat diet in mice vol.8, pp.24, 2017, https://doi.org/10.18632/oncotarget.16975
  24. Alcohol Modulation of the Postburn Hepatic Response vol.38, pp.1, 2017, https://doi.org/10.1097/bcr.0000000000000279
  25. Treatment options for alcoholic and non-alcoholic fatty liver disease: A review vol.23, pp.36, 2012, https://doi.org/10.3748/wjg.v23.i36.6549
  26. IgG Antibodies to GlcNAc β and Asialo-GM2 (GA2) Glycans as Potential Markers of Liver Damage in Chronic Hepatitis C and the Efficacy of Antiviral Treatment vol.2018, pp.None, 2018, https://doi.org/10.1155/2018/4639805
  27. Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg vol.12, pp.suppl1, 2018, https://doi.org/10.1007/s12072-017-9798-x
  28. Correlation of liver function with intestinal flora, vitamin deficiency and IL-17A in patients with liver cirrhosis vol.16, pp.5, 2012, https://doi.org/10.3892/etm.2018.6663
  29. Bacillus amyloliquefaciens SC06 Protects Mice Against High-Fat Diet-Induced Obesity and Liver Injury via Regulating Host Metabolism and Gut Microbiota vol.10, pp.None, 2019, https://doi.org/10.3389/fmicb.2019.01161
  30. Plasma levels of soluble ST 2, but not IL ‐33, correlate with the severity of alcoholic liver disease vol.23, pp.2, 2012, https://doi.org/10.1111/jcmm.13990
  31. Role of the Gut–Liver Axis in Liver Inflammation, Fibrosis, and Cancer: A Special Focus on the Gut Microbiota Relationship vol.3, pp.4, 2012, https://doi.org/10.1002/hep4.1331
  32. Role of Gut Dysbiosis in Liver Diseases: What Have We Learned So Far? vol.7, pp.4, 2012, https://doi.org/10.3390/diseases7040058
  33. Bowel Wall Thickness, Elasticity, Intestinal Permeability, and Inflammatory Cytokines in Patients with Cirrhosis and Ascites vol.94, pp.6, 2019, https://doi.org/10.3904/kjm.2019.94.6.511
  34. The role of oligosaccharides and polysaccharides of xylan and mannan in gut health of monogastric animals vol.9, pp.None, 2012, https://doi.org/10.1017/jns.2020.14
  35. The correlation between intestinal mucosal lesions and hepatic dysfunction in patients without chronic liver disease vol.99, pp.7, 2012, https://doi.org/10.1097/md.0000000000018837
  36. The assembly of integrated rat intestinal‐hepatocyte cultures vol.5, pp.1, 2012, https://doi.org/10.1002/btm2.10146
  37. Maternal hepatitis B or hepatitis C virus carrier status and long‐term infectious morbidity of the offspring: A population‐based cohort study vol.27, pp.8, 2012, https://doi.org/10.1111/jvh.13300
  38. Three-tissue microphysiological system for studying inflammatory responses in gut-liver Axis vol.22, pp.4, 2012, https://doi.org/10.1007/s10544-020-00519-y
  39. The Role of Intestinal Bacteria and Gut-Brain Axis in Hepatic Encephalopathy vol.10, pp.None, 2012, https://doi.org/10.3389/fcimb.2020.595759
  40. Interplay of cardiovascular mediators, oxidative stress and inflammation in liver disease and its complications vol.18, pp.2, 2021, https://doi.org/10.1038/s41569-020-0433-5
  41. Food-Specific IgE and IgG Antibodies in Patients With Chronic Rhinosinusitis With Nasal Polyps: A Case-Control Study vol.100, pp.3, 2021, https://doi.org/10.1177/0145561319867668
  42. Friend or Foe? Impacts of Dietary Xylans, Xylooligosaccharides, and Xylanases on Intestinal Health and Growth Performance of Monogastric Animals vol.11, pp.3, 2012, https://doi.org/10.3390/ani11030609
  43. β-blockers in advanced cirrhosis: More friend than enemy vol.27, pp.3, 2012, https://doi.org/10.3350/cmh.2020.0234
  44. Intestinal Permeability Is a Mechanical Rheostat in the Pathogenesis of Liver Cirrhosis vol.22, pp.13, 2012, https://doi.org/10.3390/ijms22136921
  45. The Role of Microbiota in Primary Sclerosing Cholangitis and Related Biliary Malignancies vol.22, pp.13, 2012, https://doi.org/10.3390/ijms22136975
  46. Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir vol.10, pp.3, 2012, https://doi.org/10.1007/s40121-021-00463-1
  47. Therapeutic challenges at the preclinical level for targeted drug development for Opisthorchis viverrini-associated cholangiocarcinoma vol.30, pp.9, 2012, https://doi.org/10.1080/13543784.2021.1955102
  48. Leaky Gut and Gut-Liver Axis in Liver Cirrhosis: Clinical Studies Update vol.15, pp.5, 2012, https://doi.org/10.5009/gnl20032
  49. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases vol.27, pp.37, 2021, https://doi.org/10.3748/wjg.v27.i37.6161
  50. Intestinal Barrier in Human Health and Disease vol.18, pp.23, 2012, https://doi.org/10.3390/ijerph182312836